RxDoctor Payments Data

Elizabeth Morgan

Ophthalmology · Anchorage, AKNPI 1811980311

Payments from drug & device makers

What this record shows

AbbVie accounts for 83.9% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $2,215, more than ten times the $51 reported in 2019.

$2,984in general payments, 2019–2025

Across 56 payments — averaging $53.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Alcon$317
  • Bausch & Lomb Americas Inc.$56
  • Katena Products, Inc. (dba Corza Medical)$33
  • NEW World Medical,inc.$20
  • Biotissue Holdings Inc.$19
  • plus $35 from 2 others

What the payments were for

  • Travel & lodging$1,56352%
  • Food & beverage$1,42148%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,984 in reported general payments places this provider in the 85th percentile of 30 ophthalmology providers in Alaska.

See all ophthalmology providers in Alaska

Medicare billing

Part B allowed, 2024
$356,723
Medicare patients
602
Services billed
2,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost70$63,562
LumiganBimatoprost72$44,708
CombiganBrimonidine Tartrate/Timolol41$20,500
RestasisCyclosporine17$20,393
Brimonidine Tartrate123$17,065
Alphagan PBrimonidine Tartrate30$14,346
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol62$14,325
Cyclosporine18$13,633
Cosopt PfDorzolamide/Timolol/Pf32$9,749
VyzultaLatanoprostene Bunod12$9,356
Travatan ZTravoprost12$7,802
Prednisolone Acetate213$7,661
Travoprost28$4,712
Latanoprost235$4,328
Dorzolamide-TimololDorzolamide/Timolol/Pf16$4,314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$2,503$99,946160 claims
Bausch & Lomb Americas Inc.Vyzulta$56$9,35612 claims
NovartisTravatan Z$17$7,80212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 30 ophthalmology providers in Alaska.

Other ophthalmology in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →